Centers | ||
|
|
|
EU-OPENSCREEN | Therapeutic Accelerator Program (TAP) | Drug Discovery Core |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Test |
The Drug Discovery Core at the University of Utah is an established Service/Recharge center that provides compound collections for screening by University of Utah Faculty. Our mission is to provide customers low-cost and efficient access to chemical... |
Partnerships |
Events |
Jobs |
Yale to Partner with Gilead to Further Cancer ResearchYale and Gilead have entered into a multi-year research collaboration to develop new treatments against cancer. Gilead will provide $40million in funding for research and other infrastructure support for the initial four years. The agreement can... View all Johnson & Johnson to Support Pain Research at Queensland UniversityJohnson & Johnson and Institute for Molecular Bioscience (IMB) at University of Queensland have entered into research agreement to develop peptides using IMB's novel assay to treat chronic pain. Johnson & Johnson and its affiliates will provide... View all Vanderbilt and Astra Zeneca to Develop New Drugs to Treat Psychosis and Other Brain DisordersUnder a new research collaboration agreement, Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) and Astra Zeneca will work together to develop compounds that act on M4 muscarinic acetylcholine receptor. The agreement entails research... View all |
No EVENTS for listing |
No Job Posts |
